NASDAQ:MYLMylan Stock Price, Forecast & News

Mylan's stock was trading at $14.47 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization. Since then, MYL shares have increased by 11.3% and is now trading at $16.10. View which stocks have been most impacted by Coronavirus.

12 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Mylan in the last year. There are currently 6 hold ratings and 6 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Mylan.

Mylan is scheduled to release its next quarterly earnings announcement on Monday, August 3rd 2020. View our earnings forecast for Mylan.

Mylan NV (NASDAQ:MYL) announced its quarterly earnings results on Monday, May, 11th. The company reported $0.90 earnings per share for the quarter, topping the Zacks' consensus estimate of $0.86 by $0.04. The business had revenue of $2.62 billion for the quarter, compared to the consensus estimate of $2.65 billion. Mylan had a net margin of 0.54% and a return on equity of 20.00%. The company's quarterly revenue was up 5.0% on a year-over-year basis. During the same quarter in the previous year, the company posted $0.82 earnings per share. View Mylan's earnings history.

Mylan issued an update on its FY 2020 Pre-Market earnings guidance on Monday, May, 11th. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $11.5-12.5 billion, compared to the consensus revenue estimate of $11.74 billion.

12 equities research analysts have issued 12-month price objectives for Mylan's shares. Their forecasts range from $17.00 to $34.50. On average, they anticipate Mylan's share price to reach $23.75 in the next twelve months. This suggests a possible upside of 47.5% from the stock's current price. View analysts' price targets for Mylan.

Media headlines about MYL stock have been trending very negative this week, InfoTrie reports. The research firm rates the sentiment of news coverage by analyzing more than six thousand news and blog sources in real time. The firm ranks coverage of public companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Mylan earned a media sentiment score of -3.8 on InfoTrie's scale. They also gave media stories about the company a news buzz of 0.0 out of 10, meaning that recent news coverage is extremely unlikely to have an effect on the stock's share price in the next several days. View the latest news about Mylan.

Mylan saw a increase in short interest during the month of June. As of June 15th, there was short interest totaling 31,480,000 shares, an increase of 13.8% from the May 31st total of 27,660,000 shares. Based on an average daily trading volume, of 7,360,000 shares, the short-interest ratio is currently 4.3 days. Approximately 6.1% of the company's shares are short sold. View Mylan's Current Options Chain.

Some companies that are related to Mylan include Johnson & Johnson (JNJ), Merck & Co., Inc. (MRK), Pfizer (PFE), Eli Lilly And Co (LLY), AbbVie (ABBV), Bristol-Myers Squibb (BMY), Zoetis (ZTS), Royalty Pharma (RPRX), Horizon Therapeutics (HZNP), Perrigo (PRGO), Jazz Pharmaceuticals (JAZZ), Nektar Therapeutics (NKTR), Pacira Biosciences (PCRX), Corcept Therapeutics (CORT) and Zogenix (ZGNX). View all competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Mylan investors own include Gilead Sciences (gild), Alibaba Group (BABA), Teva Pharmaceutical Industries (TEVA), Pfizer (PFE), NVIDIA (NVDA), Micron Technology (MU), Starbucks (SBUX), Intel (INTC), Cisco Systems (CSCO) and CVS Health (CVS).

Mylan trades on the NASDAQ under the ticker symbol "MYL."

Mylan's stock is owned by a number of retail and institutional investors. Top institutional investors include State of Alaska Department of Revenue (0.08%), Corrado Advisors LLC (0.01%), Cypress Capital Group (0.00%), Gradient Investments LLC (0.00%) and Whittier Trust Co. (0.00%). Company insiders that own Mylan stock include Goulds Bruce, Melina E Higgins, Paul Campbell, Richard A Mark, Robert J Coury and Sjoerd S Vollebregt. View institutional ownership trends for Mylan.

MYL stock was sold by a variety of institutional investors in the last quarter, including Corrado Advisors LLC, and Whittier Trust Co.. View insider buying and selling activity for Mylan.

MYL stock was bought by a variety of institutional investors in the last quarter, including State of Alaska Department of Revenue, Cypress Capital Group, and Gradient Investments LLC. Company insiders that have bought Mylan stock in the last two years include Melina E Higgins, Richard A Mark, Robert J Coury, and Sjoerd S Vollebregt. View insider buying and selling activity for Mylan.

Shares of MYL can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of MYL stock can currently be purchased for approximately $16.10.

Mylan has a market capitalization of $8.32 billion and generates $11.50 billion in revenue each year. The company earns $16.80 million in net income (profit) each year or $4.42 on an earnings per share basis. Mylan employs 35,000 workers across the globe.

The official website for Mylan is www.mylan.com.

Mylan's mailing address is 1000 MYLAN BOULEVARD, CANONSBURG PA, 15317. The company can be reached via phone at 724-514-1800 or via email at [email protected]